BioTuesdays

Tag - MTNB

HCW starts 2 omega-3 companies at buy

H.C. Wainwright launched coverage of Acasti Pharma (NASDAQ:ACST) and Matinas BioPharma (NYSE American:MTNB) with “buy” ratings and price targets of $6 and $4, respectively.

Matinas Biopharma

Maxim cuts Matinas BioPharma PT to $4 from $6

Maxim Group lowered its price target for Matinas BioPharma (NYSE American:MTNB) to $4 from $6, citing dilution from the company’s next financing. The stock closed at 68 cents on April 20. Analyst Jason McCarthy writes...